I 
117TH CONGRESS 
1ST SESSION 
H. R. 19 
To provide for certain reforms with respect to the Medicare program under 
title XVIII of the Social Security Act, the Medicaid program under 
title XIX of such Act, the Food and Drug Administration, and for 
other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 21, 2021 
Mrs. RODGERS of Washington (for herself, Mr. BRADY, Ms. FOXX, Mr. GUTH-
RIE, Mr. NUNES, and Mr. ALLEN) introduced the following bill; which 
was referred to the Committee on Energy and Commerce, and in addition 
to the Committees on Ways and Means, and the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To provide for certain reforms with respect to the Medicare 
program under title XVIII of the Social Security Act, 
the Medicaid program under title XIX of such Act, the 
Food and Drug Administration, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Lower Costs, More 
Cures Act of 2021’’. 
VerDate Sep 11 2014 
00:26 Apr 24, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H19.IH
H19
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. TABLE OF CONTENTS. 
The table of contents for this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—MEDICARE PARTS B AND D 
Subtitle A—Medicare Part B Provisions 
Sec. 101. Improvements to Medicare site-of-service transparency. 
Sec. 102. Requiring manufacturers of certain single-dose container or single-use 
package drugs payable under part B of the Medicare program 
to provide refunds with respect to discarded amounts of such 
drugs. 
Sec. 103. Providing for variation in payment for certain drugs covered under 
part B of the Medicare program. 
Sec. 104. Establishment of maximum add-on payment for drugs and 
biologicals. 
Sec. 105. Treatment of drug administration services furnished by certain ex-
cepted off-campus outpatient departments of a provider. 
Subtitle B—Drug Price Transparency 
Sec. 111. Reporting on explanation for drug price increases. 
Sec. 112. Public disclosure of drug discounts. 
Sec. 113. Study of pharmaceutical supply chain intermediaries and merger ac-
tivity. 
Sec. 114. Making prescription drug marketing sample information reported by 
manufacturers available to certain individuals and entities. 
Sec. 115. Sense of Congress regarding the need to expand commercially avail-
able drug pricing comparison platforms. 
Subtitle C—Medicare Part D Benefit Redesign 
Sec. 121. Medicare part D benefit redesign. 
Subtitle D—Other Medicare Part D Provisions 
Sec. 131. Allowing the offering of additional prescription drug plans under 
Medicare part D. 
Sec. 132. Allowing certain enrollees of prescription drug plans and MA–PD 
plans under Medicare program to spread out cost-sharing 
under certain circumstances. 
Sec. 133. Establishing a monthly cap on beneficiary incurred costs for insulin 
products and supplies under a prescription drug plan or MA– 
PD plan. 
Sec. 134. Growth rate of Medicare part D out-of-pocket cost threshold. 
TITLE II—MEDICAID 
Sec. 201. Medicaid pharmacy and therapeutics committee improvements. 
Sec. 202. GAO report on conflicts of interest in State Medicaid program drug 
use review boards and pharmacy and therapeutics (P&T) com-
mittees. 
Sec. 203. Ensuring the accuracy of manufacturer price and drug product infor-
mation under the Medicaid drug rebate program. 
VerDate Sep 11 2014 
00:26 Apr 24, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6211
E:\BILLS\H19.IH
H19
pamtmann on DSKBC07HB2PROD with BILLS